CAR therapy: the CD19 paradigm

The Journal of Clinical Investigation
Michel Sadelain

Abstract

Twenty-five years after its inception, the genetic engineering of T cells is now a therapeutic modality pursued at an increasing number of medical centers. This immunotherapeutic strategy is predicated on gene transfer technology to instruct T lymphocytes to recognize and reject tumor cells. Chimeric antigen receptors (CARs) are synthetic receptors that mediate antigen recognition, T cell activation, and - in the case of second-generation CARs - costimulation to augment T cell functionality and persistence. We demonstrated over a decade ago that human T cells engineered with a CD19-specific CAR eradicated B cell malignancies in mice. Several phase I clinical trials eventually yielded dramatic results in patients with leukemia or lymphoma, especially acute lymphoblastic leukemia (ALL). This review recounts the milestones of CD19 CAR therapy and summarizes lessons learned from the CD19 paradigm.

References

Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·F Letourneur, R D Klausner
Aug 4, 1988·Nature·M M Davis, P J Bjorkman
Oct 1, 1984·Immunological Reviews·J P AllisonB W McIntyre
Jul 18, 1995·Proceedings of the National Academy of Sciences of the United States of America·I RivièreR C Mulligan
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·B A BunnellR A Morgan
May 1, 1995·The Journal of Experimental Medicine·T Brocker, K Karjalainen
Jul 1, 1993·European Journal of Immunology·T BrockerK Karjalainen
Jan 2, 2003·Nature Reviews. Cancer·Michel SadelainRenier Brentjens
May 2, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cor H J LamersEgbert Oosterwijk
Sep 2, 2006·Science·Richard A MorganSteven A Rosenberg
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael H KershawPatrick Hwu
Sep 15, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Renier J BrentjensMichel Sadelain
Aug 30, 2008·Blood·Tucker W LeBien, Thomas F Tedder
Sep 24, 2008·Cancer Letters·Nilanjan Ghosh, William Matsui
Feb 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Carmine CarpenitoCarl H June
Mar 25, 2009·Proceedings of the National Academy of Sciences of the United States of America·Guillaume Stewart-JonesChristoph Renner
Mar 31, 2009·Current Opinion in Immunology·Michel SadelainIsabelle Rivière
Apr 23, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michael C MiloneCarl H June
Sep 24, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xiao-Song ZhongMichel Sadelain
Nov 17, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Amorette BarberCharles L Sentman

❮ Previous
Next ❯

Citations

Apr 12, 2016·Frontiers in Immunology·Ivan Borrello, Kimberly A Noonan
Nov 18, 2015·Cell Research·Jie Sun, Michel Sadelain
Mar 30, 2016·International Immunology·Matthew J Frigault, Marcela V Maus
May 21, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hiroki Torikai, Laurence Jn Cooper
Sep 14, 2016·Oncoimmunology·Aurélie Hanoteau, Muriel Moser
Dec 28, 2016·Cell Research·Rong-Fu Wang, Helen Y Wang
Dec 28, 2016·Cell Research·Laura A Johnson, Carl H June
Dec 30, 2016·Nature Reviews. Clinical Oncology·Anas YounesJulie Vose
Jul 4, 2016·Current Opinion in Immunology·Michel Sadelain
Apr 4, 2017·Current Opinion in Neurology·David A ReardonJohn H Sampson
Feb 20, 2017·Current Hematologic Malignancy Reports·Rishi Dhawan, David I Marks
Mar 28, 2017·Journal of Surgical Oncology·Carl J DeSelmPrasad S Adusumilli
Nov 30, 2016·British Journal of Haematology·Rayne H RouceHelen E Heslop
Nov 28, 2016·Hematology/oncology Clinics of North America·Anas Younes
Dec 26, 2015·Integrative Biology : Quantitative Biosciences From Nano to Macro·Anton DobrinMartin Fussenegger
Mar 27, 2018·The Journal of Gene Medicine·Samantha L GinnMohammad R Abedi
Jan 11, 2017·Transplantation·Guillaume ClaisseChristophe Mariat
Sep 1, 2017·Nature Reviews. Clinical Oncology·Jennifer N Brudno, James N Kochenderfer
Jan 24, 2018·Blood·Melody SmithMichel Sadelain
May 12, 2018·British Journal of Haematology·Cindy VargaPaul G Richardson
May 15, 2018·The American Journal of Chinese Medicine·Huiying FuQiyang Shou
Aug 16, 2017·Human Gene Therapy·Claudio MussolinoToni Cathomen
Nov 7, 2017·Leukemia & Lymphoma·Arnab GhoshRenier J Brentjens
Aug 17, 2018·Expert Review of Anticancer Therapy·Allison Barz LeahyDavid T Teachey
Nov 10, 2018·Journal of Intensive Care Medicine·Krishna ThandraSanjay Chawla
Jul 5, 2018·Journal of Medical Genetics·An-Liang XiaXiao-Jie Lu
Dec 9, 2017·Nature Reviews. Drug Discovery·Sarah A DuggerDavid B Goldstein
Jun 15, 2019·International Journal of Molecular Sciences·Dennis C HarrerNiels Schaft
Jul 30, 2019·Immunological Reviews·Elad JacobyNirali N Shah
Apr 17, 2019·The Journal of Gene Medicine·Weiqi WangHaijun Yu
Jul 7, 2019·Expert Opinion on Biological Therapy·Yu-Tzu Tai, Kenneth C Anderson
Sep 4, 2019·American Journal of Clinical Oncology·Hamzah Abu-SbeihYinghong Wang
Aug 23, 2019·Bone Marrow Transplantation·Elad Jacoby

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
transfection

Clinical Trials Mentioned

NCT00466531

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.